Windtree Therapeutics Stock Analysis

Windtree Stock Analysis Notes

The company has Price to Book (P/B) ratio of 0.61. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Windtree Therapeutics recorded earning per share (EPS) of 62.6. The entity last dividend was issued on the 29th of April 2020. The firm had 1:50 split on the 21st of February 2025. Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. Windtree Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. For more information please call Craig Fraser at 215 488 9300 or visit https://windtreetx.com.

Windtree Therapeutics Investment Alerts

Windtree Largest EPS Surprises

View All Earnings Estimates

Windtree Stock Institutional Investors

Note, although Windtree Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Windtree Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.02 M.

Windtree Profitablity

Management Efficiency

Windtree Therapeutics has return on total asset (ROA) of (0.3456) % which means that it has lost $0.3456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.129) %, meaning that it created substantial loss on money invested by shareholders. Windtree Therapeutics' management efficiency ratios could be used to measure how well Windtree Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.77 in 2026. Return On Capital Employed is likely to drop to -1.07 in 2026. At this time, Windtree Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 41.9 M in 2026, whereas Non Current Liabilities Other is likely to drop slightly above 4.2 M in 2026.

Technical Drivers

As of the 11th of February 2026, Windtree Therapeutics maintains the Standard Deviation of 11.18, mean deviation of 6.77, and Market Risk Adjusted Performance of (0.74). Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Windtree Therapeutics, as well as the relationship between them.

Windtree Therapeutics Price Movement Analysis

Windtree Therapeutics Insider Trading Activities

Windtree Therapeutics Outstanding Bonds

Windtree Therapeutics Predictive Daily Indicators

Windtree Therapeutics Forecast Models

Windtree Therapeutics' time-series forecasting models are one of many Windtree Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Windtree Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Windtree Therapeutics Bond Ratings

Windtree Therapeutics financial ratings play a critical role in determining how much Windtree Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Windtree Therapeutics' borrowing costs.

Windtree Therapeutics Debt to Cash Allocation

Windtree Therapeutics currently holds 1.82 M in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Windtree Therapeutics has a current ratio of 2.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Windtree Therapeutics' use of debt, we should always consider it together with its cash and equity.

Windtree Therapeutics Total Assets Over Time

Windtree Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Windtree Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Windtree Therapeutics Debt Ratio

5.59

It appears most of the Windtree Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Windtree Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Windtree Therapeutics, which in turn will lower the firm's financial flexibility.

Windtree Therapeutics Corporate Bonds Issued

Windtree Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Windtree Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Windtree shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Windtree Therapeutics. By using and applying Windtree Stock analysis, traders can create a robust methodology for identifying Windtree entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Windtree analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Windtree analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Windtree Therapeutics stock analysis indicators help investors evaluate how Windtree Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Windtree Therapeutics shares will generate the highest return on investment. By understating and applying Windtree Therapeutics stock analysis, traders can identify Windtree Therapeutics position entry and exit signals to maximize returns.

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.